VivoSeq
Nephrology

Polycystic Kidney Disease

17

Pipeline Programs↗

6

Active Trials↗

12

Companies Involved↗

Polycystic Kidney Disease is an emerging landscape with 17 programs across 12 companies. The most active players are Kadmon, a Sanofi Company, Esperion Therapeutics, Inc., AstraZeneca. 2 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

11/100

Mech. Concentration

20/100

Completion Rate

89/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Kadmon, a Sanofi Company

1 program

Phase 1E

Esperion Therapeutics, Inc.

1 program

Phase 2AstraZeneca logo

AstraZeneca

2 programs

Phase 3Otsuka logo

Otsuka

1 program

Phase 3Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 3AbbVie logo

AbbVie

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

15 of 17 classified programs — the dominant modality here.

12%ALL OTHERSPeptide16%Cell therapy16%

Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.

Analysis

Trial Status

17

clinical trials

Completed8 · 47%
Recruiting5 · 29%
No longer available1 · 6%
Not yet recruiting1 · 6%
Withdrawn1 · 6%
Unknown status1 · 6%

Clinical Trials

Trial Activity

17 trials

Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)
Recruiting·TThe University of Queensland·Phase 3·NCT04939935·1,174 enrolled
Well-Formulated Ketogenic Diet Polycystic Kidney Disease
Recruiting·OOhio State University·N/A·NCT06325644·20 enrolled
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
Recruiting·UUniversity of Cologne·Phase 3·NCT07280585·420 enrolled
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
Recruiting·UUniversity Medical Center Groningen·Phase 3·NCT05373264·300 enrolled
A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)
Recruiting·Otsuka logoOtsuka·Phase 3·NCT04782258·20 enrolled
Bempedoic Acid Therapy for Polycystic Kidney Disease
Not yet recruiting·—·Phase 2·NCT07282821·120 enrolled
HALT Progression of Polycystic Kidney Disease Study B
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT01885559·486 enrolled
HALT Progression of Polycystic Kidney Disease Study A
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00283686·558 enrolled
Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients
Completed·UUniversity of Kansas Medical Center·Phase 1·NCT03423810·14 enrolled
Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis
Completed·RRegional Hospital Holstebro·Phase 1·NCT00345137·75 enrolled
Lanreotide In Polycystic Kidney Disease Study
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02127437·159 enrolled
A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Completed·KKadmon Corporation, LLC·Phase 1·NCT03096080·10 enrolled
The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02134899·3 enrolled
Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease
Completed·RRoyan Institute·Phase 1·NCT02166489·6 enrolled
A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Withdrawn·Otsuka logoOtsuka·Phase 3·NCT04786574
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)